GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fosun Pharmaceutical (Group) Co Ltd (HKSE:02196) » Definitions » Shareholder Yield %

Shanghai Fosun Pharmaceutical (Group) Co (HKSE:02196) Shareholder Yield % : -5.29% (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Shanghai Fosun Pharmaceutical (Group) Co Shareholder Yield %?

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Shanghai Fosun Pharmaceutical (Group) Co's Shareholder Yield % was -5.29%.


Shanghai Fosun Pharmaceutical (Group) Co Shareholder Yield % Historical Data

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fosun Pharmaceutical (Group) Co Shareholder Yield % Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shareholder Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.49 0.44 0.66 -4.00 -4.27

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.00 -4.69 -4.22 -4.11 -4.27

Competitive Comparison of Shanghai Fosun Pharmaceutical (Group) Co's Shareholder Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Fosun Pharmaceutical (Group) Co's Shareholder Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Fosun Pharmaceutical (Group) Co's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Shanghai Fosun Pharmaceutical (Group) Co's Shareholder Yield % falls into.



Shanghai Fosun Pharmaceutical (Group) Co Shareholder Yield % Calculation

Shanghai Fosun Pharmaceutical (Group) Co's Shareholder Yield % for the quarter that ended in Dec. 2023 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=2.71 %+0 %+-5.83 %
=-3.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.


Shanghai Fosun Pharmaceutical (Group) Co  (HKSE:02196) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Shanghai Fosun Pharmaceutical (Group) Co Shareholder Yield % Related Terms

Thank you for viewing the detailed overview of Shanghai Fosun Pharmaceutical (Group) Co's Shareholder Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Fosun Pharmaceutical (Group) Co (HKSE:02196) Business Description

Traded in Other Exchanges
Address
No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233
Shanghai Fosun Pharmaceutical (Group) Co Ltd is a specialty and generic drug manufacturing company. Shanghai Fosun maintains five business segments, including Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. Most of the company's revenue is generated by its Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Shanghai Fosun Pharmaceutical (Group) Co (HKSE:02196) Headlines

No Headlines